Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Towards a standard pathological and molecular characterization of recurrent glioma in adults: a RANO effort.

Haider AS, van den Bent M, Wen PY, Vogelbaum MA, Chang S, Canoll PD, Horbinski CM, Huse JT.

Neuro Oncol. 2019 Dec 17. pii: noz233. doi: 10.1093/neuonc/noz233. [Epub ahead of print]

PMID:
31844891
2.

Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.

Cimino PJ, Zager M, McFerrin L, Wirsching HG, Bolouri H, Hentschel B, von Deimling A, Jones D, Reifenberger G, Weller M, Holland EC.

Acta Neuropathol Commun. 2017 May 22;5(1):39. doi: 10.1186/s40478-017-0443-7.

3.

Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group.

Vogelbaum MA, Jost S, Aghi MK, Heimberger AB, Sampson JH, Wen PY, Macdonald DR, Van den Bent MJ, Chang SM.

Neurosurgery. 2012 Jan;70(1):234-43; discussion 243-4. doi: 10.1227/NEU.0b013e318223f5a7. Review.

PMID:
21593697
4.

Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Nahed BV, Redjal N, Brat DJ, Chi AS, Oh K, Batchelor TT, Ryken TC, Kalkanis SN, Olson JJ.

J Neurooncol. 2015 Dec;125(3):609-30. doi: 10.1007/s11060-015-1910-2. Epub 2015 Nov 3. Review.

PMID:
26530264
5.

[Histological and molecular classification of gliomas].

Figarella-Branger D, Colin C, Coulibaly B, Quilichini B, Maues De Paula A, Fernandez C, Bouvier C.

Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):505-15. doi: 10.1016/j.neurol.2008.03.011. Epub 2008 Jun 10. Review. French.

PMID:
18565348
6.

The role of radiotherapy in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Ryken TC, Parney I, Buatti J, Kalkanis SN, Olson JJ.

J Neurooncol. 2015 Dec;125(3):551-83. doi: 10.1007/s11060-015-1948-1. Epub 2015 Nov 3. Review.

PMID:
26530266
7.

Central nervous system.

Adamson DC, Rasheed BA, McLendon RE, Bigner DD.

Cancer Biomark. 2010;9(1-6):193-210. doi: 10.3233/CBM-2011-0177. Review.

PMID:
22112477
8.

Evidence Brief: Comparative Effectiveness of Appointment Recall Reminder Procedures for Follow-up Appointments.

Peterson K, McCleery E, Anderson J, Waldrip K, Helfand M.

VA Evidence Synthesis Program Evidence Briefs [Internet]. Washington (DC): Department of Veterans Affairs (US); 2011-.
2015 Jul.

9.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
10.

Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities.

Wood MD, Halfpenny AM, Moore SR.

Diagn Pathol. 2019 Apr 9;14(1):29. doi: 10.1186/s13000-019-0802-8. Review.

11.
12.

Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas.

Jaspan T, Morgan PS, Warmuth-Metz M, Sanchez Aliaga E, Warren D, Calmon R, Grill J, Hargrave D, Garcia J, Zahlmann G.

AJNR Am J Neuroradiol. 2016 Sep;37(9):1581-7. doi: 10.3174/ajnr.A4782. Epub 2016 Apr 28.

13.

Exploitation of immune mechanisms in the treatment of central nervous system cancer.

Pollack IF, Okada H, Chambers WH.

Semin Pediatr Neurol. 2000 Jun;7(2):131-43. Review.

PMID:
10914414
14.

The Role of Molecular Diagnostics in the Management of Patients with Gliomas.

Wirsching HG, Weller M.

Curr Treat Options Oncol. 2016 Oct;17(10):51. doi: 10.1007/s11864-016-0430-4. Review.

PMID:
27501915
15.

Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults.

Rodriguez FJ, Vizcaino MA, Lin MT.

J Mol Diagn. 2016 Sep;18(5):620-634. doi: 10.1016/j.jmoldx.2016.05.005. Review. Erratum in: J Mol Diagn. 2016 Nov;18(6):933.

16.

The role of imaging in the management of adults with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Fouke SJ, Benzinger T, Gibson D, Ryken TC, Kalkanis SN, Olson JJ.

J Neurooncol. 2015 Dec;125(3):457-79. doi: 10.1007/s11060-015-1908-9. Epub 2015 Nov 3. Review.

PMID:
26530262
17.

Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium.

GLASS Consortium.

Neuro Oncol. 2018 Jun 18;20(7):873-884. doi: 10.1093/neuonc/noy020. Review.

18.

Recurrent pediatric central nervous system low-grade gliomas: the role of surveillance neuroimaging in asymptomatic children.

Udaka YT, Yeh-Nayre LA, Amene CS, VandenBerg SR, Levy ML, Crawford JR.

J Neurosurg Pediatr. 2013 Feb;11(2):119-26. doi: 10.3171/2012.10.PEDS12307. Epub 2012 Nov 16.

PMID:
23157391
19.

[Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. German version].

Malzkorn B, Reifenberger G.

Pathologe. 2019 Mar;40(2):131-139. doi: 10.1007/s00292-019-0575-6. Review. German.

PMID:
30790013
20.

Advances in the molecular genetics of gliomas - implications for classification and therapy.

Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, Weller M.

Nat Rev Clin Oncol. 2017 Jul;14(7):434-452. doi: 10.1038/nrclinonc.2016.204. Epub 2016 Dec 29. Review.

Supplemental Content

Support Center